Literature DB >> 3390974

Neuropathological findings in penicillamine-treated patients with Wilson's disease.

D S Horoupian1, I Sternlieb, I H Scheinberg.   

Abstract

We report the terminal neurological impairment, amount of penicillamine taken, neuropathology and cerebral copper content of eleven patients with Wilson's disease treated for as long as 17 years. Therapy was accompanied by complete resolution of neurologic symptomatology in five patients and significant improvement in the neuro-psychiatric manifestations in six. Abnormal glial cells were seen in all the brains; gross or micro-cavitary changes were present in the putamina of eight. Of the four sets of observations, there was virtually no correlation between the degree of neurologic dysfunction - if any - in the months before death and either the amount of penicillamine taken or the cerebral copper content. There was, however, a fair degree of correlation between the severity of the neuropathologic findings and cerebral copper content.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390974

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  12 in total

Review 1.  Neuroimaging in Wilson disease.

Authors:  H N van Wassenaer-van Hall
Journal:  Metab Brain Dis       Date:  1997-03       Impact factor: 3.584

Review 2.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

4.  Lenticular nucleus hyperechogenicity in Wilson's disease reflects local copper, but not iron accumulation.

Authors:  Uwe Walter; Marta Skowrońska; Tomasz Litwin; Grażyna Maria Szpak; Katarzyna Jabłonka-Salach; David Skoloudík; Ewa Bulska; Anna Członkowska
Journal:  J Neural Transm (Vienna)       Date:  2014-03-11       Impact factor: 3.575

5.  Brain proton magnetic spectroscopy in long-term treatment of Wilson's disease patients.

Authors:  Beata Tarnacka; Wojciech Szeszkowski; Marek Gołębiowski; Anna Członkowska
Journal:  Metab Brain Dis       Date:  2010-09-14       Impact factor: 3.584

6.  Fine motor skills disorders in the course of Wilson's disease.

Authors:  Peter Albrecht Günther; Hans-Juergen Kühn; Thomas Villmann; Wieland Hermann
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

7.  Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.

Authors:  G Schlaug; H Hefter; B Nebeling; V Engelbrecht; P Weiss; G Stöcklin; R J Seitz
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

8.  Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.

Authors:  H Hefter; T Kuwert; H Herzog; G Arendt; W Stremmel; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849

Review 9.  Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation.

Authors:  Jan Aaseth; Jan Alexander; Geir Bjørklund; Knut Hestad; Petr Dusek; Per M Roos; Urban Alehagen
Journal:  Biometals       Date:  2016-08-16       Impact factor: 2.949

10.  Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients.

Authors:  Meghri Katerji; Kassem Barada; Mustapha Jomaa; Firas Kobeissy; Ahmad-Kareem Makkawi; Wassim Abou-Kheir; Julnar Usta
Journal:  Front Mol Neurosci       Date:  2017-01-31       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.